Login
Sol Gel Technologies Ltd logo

Sol Gel Technologies Ltd

sol-gel.com

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 28 full-time employees. The company went IPO on 2018-02-01. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Financial Snapshot

Revenue
TTM
$18.47M
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$1.046M
Current Assets
2026 Q1
$55.79M
Current Liabilities
2026 Q1
$6.313M
Current Ratio
2026 Q1
883.72%
Total Assets
2026 Q1
$58.55M
Total Liabilities
2026 Q1
$7.144M
Book Value
2026 Q1
51.41M
Cash
2026 Q1
$10.14M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
$275.0K

Stock Price

Loading...
Market Cap: $268.02 Million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support